JP2022503847A5 - - Google Patents

Info

Publication number
JP2022503847A5
JP2022503847A5 JP2021517408A JP2021517408A JP2022503847A5 JP 2022503847 A5 JP2022503847 A5 JP 2022503847A5 JP 2021517408 A JP2021517408 A JP 2021517408A JP 2021517408 A JP2021517408 A JP 2021517408A JP 2022503847 A5 JP2022503847 A5 JP 2022503847A5
Authority
JP
Japan
Prior art keywords
composition according
nk1r
progenitor cells
msc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053293 external-priority patent/WO2020069215A1/en
Publication of JP2022503847A publication Critical patent/JP2022503847A/ja
Publication of JP2022503847A5 publication Critical patent/JP2022503847A5/ja
Pending legal-status Critical Current

Links

JP2021517408A 2018-09-27 2019-09-26 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞 Pending JP2022503847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737627P 2018-09-27 2018-09-27
US62/737,627 2018-09-27
PCT/US2019/053293 WO2020069215A1 (en) 2018-09-27 2019-09-26 Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Publications (2)

Publication Number Publication Date
JP2022503847A JP2022503847A (ja) 2022-01-12
JP2022503847A5 true JP2022503847A5 (https=) 2022-09-30

Family

ID=69945385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517408A Pending JP2022503847A (ja) 2018-09-27 2019-09-26 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞

Country Status (4)

Country Link
US (2) US11642377B2 (https=)
EP (1) EP3856203A4 (https=)
JP (1) JP2022503847A (https=)
WO (1) WO2020069215A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069215A1 (en) 2018-09-27 2020-04-02 Biocardia, Inc. Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
NZ608734A (en) 2010-08-27 2014-09-26 Univ Miami Bone marrow derived cd271 precursor cells for cardiac repair
WO2020069215A1 (en) 2018-09-27 2020-04-02 Biocardia, Inc. Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Similar Documents

Publication Publication Date Title
Musialek et al. Original paper Myocardial regeneration strategy using Wharton’s jelly mesenchymal stem cells as an off-the-shelf ‘unlimited’therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study
Xu et al. Circulating mesenchymal stem cells and their clinical implications
Minguell et al. Biology and clinical utilization of mesenchymal progenitor cells
Kim et al. The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease
Bertozzi et al. The biological and clinical basis for the use of adipose-derived stem cells in the field of wound healing
Suzuki et al. Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease
De Francesco et al. Human adipose stem cells: from bench to bedside
Sart et al. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications
Stoltz et al. Stem cells and regenerative medicine: myth or reality of the 21th century
Yan et al. Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy
Kim et al. Muscle regeneration by adipose tissue-derived adult stem cells attached to injectable PLGA spheres
JP5633859B2 (ja) 脂肪組織由来間葉系幹細胞を含有する免疫抑制剤及びその用途
JP2015500810A5 (https=)
JP2013510582A (ja) 間葉幹細胞の球状集合体
Nemeth et al. Bone marrow stromal cells as immunomodulators. A primer for dermatologists
Bartel et al. The aastrom experience
Fidelis-de-Oliveira et al. Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts
Szydlak Mesenchymal stem cells in ischemic tissue regeneration
Ohnishi et al. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure
Fang et al. Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats
Van Linthout et al. Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond
Şovrea et al. State of the art in human adipose stem cells and their role in therapy
Chen et al. Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy?
Lian et al. In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice
Wang et al. Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway